Press Release

On 30th March 2020, HitGen Inc announces that its small-molecule tyrosine kinase inhibitor HG030 has obtained IND approval from the CDE (Center For Drug Evaluation), NMPA, China’s Regulatory Authority for clinical trials and new products approval. The potential indications for HG030 are against the solid tumors harboring NTRK1/2/3/ROS1 fusion genes.

Chengdu, China, March 11, 2020 HitGen Inc. (HitGen) announced today that HitGen and Kaken Pharmaceutical Co., Ltd. have entered into a license agreement to develop a novel class of drugs. This is the second licensing agreement. The licensed compounds were identified using HitGen’s leading technology platform, which involved screening large DNA encoded libraries, containing over 400 billion of small molecules with drug-like properties synthesized on chemically diverse scaffolds. A number of novel small molecule leads for an undisclosed target nominated by Kaken were the subject of this license agreement.

CHENGDU, China, January 15, 2020 -- HitGen Inc. today announced that it has entered into a drug discovery research collaboration with Kymera Therapeutics, Inc.,to identify small molecule leads against targets of interest to Kymera. HitGen will apply its platform technology, based on the design, synthesis and screening of DNA-encoded libraries (DEL) to discover compounds that bind to certain targets. The identified compounds will be exclusively licensed to Kymera. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment and will be eligible for milestone payments from Kymera.

Chengdu, China, December 18, 2019 HitGen Inc. (HitGen) announced today that HitGen and Mitsubishi Tanabe Pharma Corporation (MTPC) have entered into a license agreement to develop a novel class of drugs. The licensed compounds were identified using HitGen’s leading technology platform, which involved screening large DNA encoded libraries, containing more than 400 billion of small molecules with drug-like properties synthesized on chemically diverse scaffolds.

Chengdu, China, December 9th, 2019 – HitGen Inc. (“HitGen”) is pleased to announce that the company has entered into a strategic collaboration with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to design and build novel DNA-encoded libraries (“DELs”) to discover unique small molecule assets. The collaboration will apply HitGen’s advanced technology platform and research capabilities in the design and synthesis of multiple proprietary DELs for Janssen drug discovery and development efforts.The collaboration was facilitated by Johnson & Johnson Innovation and builds upon the success of earlier agreements for the identification of hits using HitGen’s platform for various priority targets.

Ballerup, Denmark and Chengdu, China, November 12, 2019 – LEO Pharma A/S and HitGen Inc. are pleased to announce that HitGen and LEO Pharma expands their collaboration with a license to develop a novel class of drugs for a dermatology indication.

Chengdu, China,October 16th,2019 – HitGen Inc. today announced that it has entered into a drug discovery research collaboration with Galapagos NV to identify potential small molecule leads against targets of interest to Galapagos NV.In this collaboration,HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads. Under the terms of the agreement,HitGen will receive an undisclosed upfront payment and will be eligible for milestone payments from Galapagos NV.

Chengdu, China，June 3rd, 2019-HitGen Inc today announced that it has entered into adrug discovery research collaboration with Gilead Sciences to identify potential small molecule leads against targets of interest to Gilead.In this collaboration,HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads. Under the terms of the agreement,HitGen will receive an undisclosed upfront payment and will be eligible formilestone payments from Gilead.

Kenilworth, N.J., U.S.A. CHENGDU, CHINA – April 18, 2019, HitGen Inc., announced today that it has achieved a milestone in its discovery alliance with Merck & Co. Inc., Kenilworth NJ, USA, known as MSD outside the United States and Canada. The milestone was for the identification of candidates meeting pre-defined criteria, representing the 3rd discovery program between the two companies for which HitGen has achieved this milestone. This achievement entitles HitGen to receive an undisclosed payment per the research collaboration agreement between both companies announced March 14, 2017.

Chengdu, China, April 11, 2019 HitGen Inc. announced today that HitGen Inc. and Kaken Pharmaceutical Co., Ltd. have entered into a license agreement to develop a novel class of drugs. The licensed compounds were identified using HitGen’s leading technology platform, which involved screening large DNA encoded libraries, containing over 400 billion of small molecules with drug-like properties synthesized on chemically diverse scaffolds. A number of novel small molecule leads for an undisclosed target nominated by Kaken were the subject of this license agreement.